Last checked at 12 Aug 2021 10:20
Hardman & Co Research Hardman & Co Research: Q&A with Brian Moretta on Fidelity Special Values: FSV outperforms the UK All-Share by 4.9% per annum 12-Aug-2021 / 10:20 GMT/BST Hardman & Co Video | Q&A with Brian Moretta on Fidelity Special Values (FSV) | FSV outperforms the UK All-Share by 4.9% per annum Fidelity Special Values (FSV) is the topic of conversation when Brian Moretta talks to DirectorsTalk. Brian explains the thinking behind his report, talks about the contrarianism, the features the process brings to the portfolio, risks and the outlook for the trust. Listen to the interview here: https://vimeo.com/583789078
To read the transcript of this interview, click here Read our latest report on FSV here If you are interested in meeting the company, you can register your interest here
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. |
1226019 12-Aug-2021
corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.